| Literature DB >> 24783986 |
Saami Khalifian1, Philip S Brazio2, Raja Mohan2, Cynthia Shaffer2, Gerald Brandacher3, Rolf N Barth4, Eduardo D Rodriguez5.
Abstract
Since the first facial transplantation in 2005, 28 have been done worldwide with encouraging immunological, functional, psychological, and aesthetic outcomes. Unlike solid organ transplantation, which is potentially life-saving, facial transplantation is life-changing. This difference has generated ethical concerns about the exposure of otherwise young and healthy individuals to the sequelae of lifelong, high-dose, multidrug immunosuppression. Nevertheless, advances in immunomodulatory and immunosuppressive protocols, microsurgical techniques, and computer-aided surgical planning have enabled broader clinical application of this procedure to patients. Although episodes of acute skin rejection continue to pose a serious threat to face transplant recipients, all cases have been controlled with conventional immunosuppressive regimens, and no cases of chronic rejection have been reported.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24783986 DOI: 10.1016/S0140-6736(13)62632-X
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321